In 2021-22 we continued to take a lead role in adapting to the health environment that has been significantly impacted by COVID-19. Medicines and medical devices associated with COVID-19 were prioritised and their safety and efficacy assessed through stringent pre-market assessments and thorough post-market safety monitoring. Post-market review of COVID-19-related devices including face masks, respirators, and test kits was also a major activity.
